The turbulent regulatory journey of simufilam reveals the complexities of pharmaceutical approval, shadowed by allegations of misleading trial data and research manipulation.
Despite the ongoing scrutiny and allegations leading to a $40 million settlement with the S.E.C., Cassava Sciences continues advanced trials for simufilam, suggesting persistent hope in its efficacy.
#alzheimers-disease #pharmaceutical-regulation #clinical-trials #cassava-sciences #health-care-ethics
Collection
[
|
...
]